Iron deficiency anemia in heart failure

Heart Failure Reviews

Volumn 18, Issue 4, 2013, Pages 485-501

  Arora, Natasha P ^a   Ghali, Jalal K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Anemia; Heart failure; Iron deficiency; Iron therapy

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ATHEROSCLEROSIS; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE EXACERBATION; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEART FAILURE; HEART TRANSPLANTATION; HEMOGLOBIN DETERMINATION; HUMAN; INCIDENCE; INFLAMMATORY DISEASE; IRON BALANCE; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; IRON THERAPY; KIDNEY FAILURE; METABOLIC REGULATION; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SYMPTOM; SYSTOLIC DYSFUNCTION; TREATMENT RESPONSE;

ANEMIA, IRON-DEFICIENCY; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; IRON; IRON COMPOUNDS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UNITED STATES;

EID: 84879105015     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-012-9342-y     Document Type: Review

References (126)

1. Lindenfeld J (2005) Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 149(3):391-401. doi: 10.1016/j.ahj.2004.08.039
2. Ghali JK (2009) Anemia and heart failure. Curr Opin Cardiol 24(2):172-178. doi: 10.1097/HCO.0b013e328324ecec
3. WHO (2001) Iron deficiency anaemia: assessment, prevention and control: a guide for programme managers. WHO
4. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52(10):818-827. doi: 10.1016/j.jacc.2008.04.061
5. Zuccala G, Marzetti E, Cesari M, Lo Monaco MR, Antonica L, Cocchi A, Carbonin P, Bernabei R (2005) Correlates of cognitive impairment among patients with heart failure: results of a multicenter survey. Am J Med 118(5):496-502. doi: 10.1016/j.amjmed.2005.01.030
6. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39(11):1780-1786
7. Kalra PR, Bolger AP, Francis DP, Genth-Zotz S, Sharma R, Ponikowski PP, Poole-Wilson PA, Coats AJ, Anker SD (2003) Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 91(7):888-891
8. Salisbury AC, Kosiborod M (2010) Outcomes associated with anemia in patients with heart failure. Heart failure clin 6(3):359-372. doi: 10.1016/j.hfc.2010.03.005
9. Adams KF Jr, Pina IL, Ghali JK, Wagoner LE, Dunlap SH, Schwartz TA, Stough WG, Mehra MR, Felker GM, Chiong JR, Patterson JH, Kim J, Butler J, Oren RM (2009) Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. Am Heart J 158(6):965-971. doi: 10.1016/j.ahj.2009.10.015
10. Eschbach JW (2002) Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. J Am Soc Nephrol (JASN) 13(5):1412-1414
11. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ (2007) Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 28(2):166-171. doi: 10.1093/eurheartj/ehl419
12. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, Mancini DM (2003) Hemodilution is common in patients with advanced heart failure. Circulation 107(2):226-229
13. Adlbrecht C, Kommata S, Hulsmann M, Szekeres T, Bieglmayer C, Strunk G, Karanikas G, Berger R, Mortl D, Kletter K, Maurer G, Lang IM, Pacher R (2008) Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 29(19):2343-2350. doi: 10.1093/eurheartj/ehn359
14. Weiss G, Goodnough LT (2005) Anemia of chronic disease. New Engl J Med 352(10):1011-1023. doi: 10.1056/NEJMra041809
15. Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA (2005) Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45(3):391-399. doi: 10.1016/j.jacc.2004.10.038
16. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH (2005) Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112(12):1743-1747. doi: 10.1161/CIRCULATIONAHA.105.549121
17. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN (2005) Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112(8):1121-1127. doi: 10.1161/CIRCULATIONAHA.104.512988
18. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, Remme W, Moullet C, Swedberg K, Cleland JG, Poole-Wilson PA (2006) The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 27(12):1440-1446. doi: 10.1093/eurheartj/ehl012
19. von Haehling S, van Veldhuisen DJ, Roughton M, Babalis D, de Boer RA, Coats AJ, Manzano L, Flather M, Anker SD (2011) Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. Eur J Heart Fail 13(6):656-663. doi: 10.1093/eurjhf/hfr044
20. Westenbrink BD, Voors AA, de Boer RA, Schuringa JJ, Klinkenberg T, van der Harst P, Vellenga E, van Veldhuisen DJ, van Gilst WH (2010) Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail 12(7):676-684. doi: 10.1093/eurjhf/hfq061
21. Kissel CK, Lehmann R, Assmus B, Aicher A, Honold J, Fischer-Rasokat U, Heeschen C, Spyridopoulos I, Dimmeler S, Zeiher AM (2007) Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 49(24):2341-2349. doi: 10.1016/j.jacc.2007.01.095
22. Okonko DO, Crosato M, Kalra PR, Cicoira M, John M, Doehner W, Coats AJ, Poole-Wilson PA, Anker SD (2005) Association of deranged adrenal steroid metabolism with anemia in chronic heart failure. Am J Cardiol 96(1):101-103. doi: 10.1016/j.amjcard.2005.02.053
23. van der Meer P, Lok DJ, Januzzi JL, de la Porte PW, Lipsic E, van Wijngaarden J, Voors AA, van Gilst WH, van Veldhuisen DJ (2008) Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 29(12):1510-1515. doi: 10.1093/eurheartj/ehn205
24. Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL (2004) Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 147(5):924-930. doi: 10.1016/j.ahj.2003.11.007
25. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26(21):2232-2237. doi: 10.1093/eurheartj/ehi388
26. Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 107(2):223-225
27. Duffy TP (2004) Microcytic and hypochromic anemias. Cecil Textbook of Medicine, Saunders
28. de Silva R, Rigby AS, Witte KK, Nikitin NP, Tin L, Goode K, Bhandari S, Clark AL, Cleland JG (2006) Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 98(3):391-398. doi: 10.1016/j.amjcard.2006.01.107
29. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48(12):2485-2489. doi: 10.1016/j.jacc.2006.08.034
30. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. New Engl J Med 361(25):2436-2448. doi: 10.1056/NEJMoa0908355
31. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31(15):1872-1880. doi: 10.1093/eurheartj/ehq158
32. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA (2011) Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 58(12):1241-1251. doi: 10.1016/j.jacc.2011.04.040
33. Lee G (1993) Iron deficiency and iron-deficiency anemia. Wintrobe's clinical haematology. Lea & Febiger, Philadelphia
34. Zimmermann MB, Hurrell RF (2007) Nutritional iron deficiency. Lancet 370(9586):511-520. doi: 10.1016/S0140-6736(07)61235-5
35. Weiss G (2009) Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 1790(7):682-693. doi: 10.1016/j.bbagen.2008.08.006
36. Handelman GJ, Levin NW (2008) Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 13(4):393-404. doi: 10.1007/s10741-008-9086-x
37. Cunietti E, Chiari MM, Monti M, Engaddi I, Berlusconi A, Neri MC, De Luca P (2004) Distortion of iron status indices by acute inflammation in older hospitalized patients. Arch Gerontol Geriatr 39(1):35-42. doi: 10.1016/j.archger.2003.12.005
38. Means RT Jr, Allen J, Sears DA, Schuster SJ (1999) Serum soluble transferrin receptor and the prediction of marrow aspirate iron results in a heterogeneous group of patients. Clin Lab Haematol 21(3):161-167
39. Cook JD, Skikne BS, Baynes RD (1993) Serum transferrin receptor. Annu Rev Med 44:63-74. doi: 10.1146/annurev.me.44.020193.000431
40. Beguin Y, Clemons GK, Pootrakul P, Fillet G (1993) Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 81(4):1067-1076
41. Punnonen K, Irjala K, Rajamaki A (1997) Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 89(3):1052-1057
42. Thomas C, Kirschbaum A, Boehm D, Thomas L (2006) The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy. Med Oncol 23(1):23-36. doi: 10.1385/MO:23:1:23
43. Thomas C, Thomas L (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48(7):1066-1076
44. Leszek P, Sochanowicz B, Szperl M, Kolsut P, Brzoska K, Piotrowski W, Rywik TM, Danko B, Polkowska-Motrenko H, Rozanski JM, Kruszewski M (2011) Myocardial iron homeostasis in advanced chronic heart failure patients. Int J Cardiol. doi: 10.1016/j.ijcard.2011.08.006
45. Naito Y, Tsujino T, Fujimori Y, Sawada H, Akahori H, Hirotani S, Ohyanagi M, Masuyama T (2011) Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats. J Hypertens 29(4):741-748. doi: 10.1097/HJH.0b013e3283434784
46. Merle U, Fein E, Gehrke SG, Stremmel W, Kulaksiz H (2007) The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 148(6):2663-2668. doi: 10.1210/en.2006-1331
47. Matsumoto M, Tsujino T, Lee-Kawabata M, Naito Y, Akahori H, Sakoda T, Ohyanagi M, Tomosugi N, Masuyama T (2010) Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. Circ J Off J Jap Circu Soc 74(2):301-306
48. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S (2002) Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Nat Acad Sci USA 99(7):4596-4601. doi: 10.1073/pnas.072632499
49. Ganz T, Nemeth E (2011) Hepcidin and disorders of iron metabolism. Annu Rev Med 62:347-360. doi: 10.1146/annurev-med-050109-142444
50. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306(5704):2090-2093. doi: 10.1126/science.1104742
51. van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, Braam B, Gaillard CA (2010) Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 12(9):943-950. doi: 10.1093/eurjhf/hfq099
52. Haas JD, Brownlie Tt (2001) Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 131(2S-2):676S-688S; discussion 688S-690S
53. Cairo G, Bernuzzi F, Recalcati S (2006) A precious metal: iron, an essential nutrient for all cells. Genes Nutr 1(1):25-39. doi: 10.1007/BF02829934
54. Anderson GJ, Vulpe CD (2009) Mammalian iron transport. Cell Mol Life Sci (CMLS) 66(20):3241-3261. doi: 10.1007/s00018-009-0051-1
55. Andrews NC (1999) Disorders of iron metabolism. New Engl J Med 341(26):1986-1995. doi: 10.1056/NEJM199912233412607
56. Sutak R, Lesuisse E, Tachezy J, Richardson DR (2008) Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol 16(6):261-268. doi: 10.1016/j.tim.2008.03.005
57. Wilson MT, Reeder BJ (2008) Oxygen-binding haem proteins. Exp Physiol 93(1):128-132. doi: 10.1113/expphysiol.2007.039735
58. Gomollon F, Gisbert JP (2009) Anemia and inflammatory bowel diseases. World J Gastroenterol (WJG) 15(37):4659-4665
59. Anker SD, Sharma R (2002) The syndrome of cardiac cachexia. Int J Cardiol 85(1):51-66
60. Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J (2005) Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 109(3):277-286. doi: 10.1042/CS20040278
61. Katz SD, Zheng H (2002) Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol 9(2):215-225
62. Brownlie Tt, Utermohlen V, Hinton PS, Haas JD (2004) Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 79(3):437-443
63. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC (2011) Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 8(9):485-493. doi: 10.1038/nrcardio.2011.77
64. Maeder MT, Khammy O, dos Remedios C, Kaye DM (2011) Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol 58(5):474-480. doi: 10.1016/j.jacc.2011.01.059
65. Jankowska EA, Ponikowski P (2010) Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin 6(3):295-304. doi: 10.1016/j.hfc.2010.03.003
66. Parikh A, Natarajan S, Lipsitz SR, Katz SD (2011) Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: prevalence and associations with anemia and inflammation. Circ Heart Fail 4(5):599-606. doi: 10.1161/ CIRCHEARTFAILURE.111.960906
67. Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabro A, Campagna SM, Nuti R (2006) Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152(6):1096 e1099-1015. doi: 10.1016/j.ahj.2006.08.005
68. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE (1996) A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50(5):1694-1699
69. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S (2005) A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68(6):2846-2856. doi: 10.1111/j.1523-1755.2005.00758.x
70. Toblli JE, Lombrana A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50(17):1657-1665. doi: 10.1016/j.jacc.2007.07.029
71. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P (2008) Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51(2):103-112. doi: 10.1016/j.jacc.2007.09.036
72. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM (2006) Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48(6):1225-1227. doi: 10.1016/j.jacc.2006.07.015
73. Usmanov RI, Zueva EB, Silverberg DS, Shaked M (2008) Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 21(2):236-242
74. Drakos SG, Anastasiou-Nana MI, Malliaras KG, Nanas JN (2009) Anemia in chronic heart failure. Congest Heart Fail 15(2):87-92. doi: 10.1111/j.1751-7133. 2009.00049.x
75. Brutsaert TD, Hernandez-Cordero S, Rivera J, Viola T, Hughes G, Haas JD (2003) Iron supplementation improves progressive fatigue resistance during dynamic knee extensor exercise in iron-depleted, nonanemic women. Am J Clin Nutr 77(2):441-448
76. Danielson BG, Salmonson T, Derendorf H, Geisser P (1996) Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 46(6):615-621
77. Seligman PA, Dahl NV, Strobos J, Kimko HC, Schleicher RB, Jones M, Ducharme MP (2004) Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy 24(5):574-583
78. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J (1999) Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis Off J Nat Kidney Found 33(3):471-482
79. Mircescu G, Garneata L, Capusa C, Ursea N (2006) Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 21(1):120-124. doi: 10.1093/ndt/gfi087
80. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K (2000) Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 15(11):1827-1834
81. Fishbane S (2003) Safety in iron management. Am J Kidney Dis Off J Nat Kidney Found 41(5 Suppl):18-26
82. Agarwal R, Vasavada N, Sachs NG, Chase S (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65(6):2279-2289. doi: 10.1111/j.1523-1755.2004.00648.x
83. Agarwal R, Rizkala AR, Kaskas MO, Minasian R, Trout JR (2007) Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 72(5):638-642. doi: 10.1038/sj.ki.5002422
84. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N (2007) Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Cardiac Fail 13(1):14-17. doi: 10.1016/j.cardfail.2006.09.007
85. Yuan XM, Li W (2008) Iron involvement in multiple signaling pathways of atherosclerosis: a revisited hypothesis. Curr Med Chem 15(21):2157-2172
86. Sullivan JL (2004) Is stored iron safe? J Lab Clin Med 144(6):280-284. doi: 10.1016/j.lab.2004.10.006
87. Lee TS, Shiao MS, Pan CC, Chau LY (1999) Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 99(9):1222-1229
88. Facchini FS, Saylor KL (2002) Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci 967:342-351
89. Lee HT, Chiu LL, Lee TS, Tsai HL, Chau LY (2003) Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. J Biomed Sci 10(5):510-517. doi: 10.1159/000072378
90. Patt A, Horesh IR, Berger EM, Harken AH, Repine JE (1990) Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. Journal of pediatric surgery 25(2):224-227; discussion 227-228
91. Ponraj D, Makjanic J, Thong PS, Tan BK, Watt F (1999) The onset of atherosclerotic lesion formation in hypercholesterolemic rabbits is delayed by iron depletion. FEBS Lett 459(2):218-222
92. van Jaarsveld H, Pool GF (2002) Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis 161(2):395-402
93. Kruszewski M (2004) The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol 51(2):471-480. doi: 035001471
94. McCord JM (1998) Iron, free radicals, and oxidative injury. Semin Hematol 35(1):5-12
95. Gey KF (1993) Prospects for the prevention of free radical disease, regarding cancer and cardiovascular disease. Br Med Bull 49(3):679-699
96. Corti MC, Gaziano M, Hennekens CH (1997) Iron status and risk of cardiovascular disease. Ann Epidemiol 7(1):62-68
97. Wardman P, Candeias LP (1996) Fenton chemistry: an introduction. Radiat Res 145(5):523-531
98. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, Chen AF (2003) Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 107(7):1053-1058
99. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Investig 97(8):1916-1923. doi: 10.1172/JCI118623
100. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT (1997) Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Nat Acad Sci USA 94(26):14483-14488
101. Krieglstein CF, Granger DN (2001) Adhesion molecules and their role in vascular disease. Am J Hypertens 14(6 Pt 2):44S-54S
102. Ley K, Huo Y (2001) VCAM-1 is critical in atherosclerosis. J Clin Investig 107(10):1209-1210. doi: 10.1172/JCI13005
103. Quinn MT, Gauss KA (2004) Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol 76(4):760-781. doi: 10.1189/jlb.0404216
104. Yu L, Zhen L, Dinauer MC (1997) Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits. J Biol Chem 272(43):27288-27294
105. Taille C, El-Benna J, Lanone S, Dang MC, Ogier-Denis E, Aubier M, Boczkowski J (2004) Induction of heme oxygenase-1 inhibits NAD(P)H oxidase activity by down-regulating cytochrome b558 expression via the reduction of heme availability. J Biol Chem 279(27):28681-28688. doi: 10.1074/jbc.M310661200
106. Li L, Frei B (2009) Prolonged exposure to LPS increases iron, heme, and p22phox levels and NADPH oxidase activity in human aortic endothelial cells: inhibition by desferrioxamine. Arterioscler Thromb Vasc Biol 29(5):732-738. doi: 10.1161/ATVBAHA.108.183210
107. Minqin R, Watt F, Huat BT, Halliwell B (2003) Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. Free Radical Biol Med 34(6):746-752
108. Thong PS, Selley M, Watt F (1996) Elemental changes in atherosclerotic lesions using nuclear microscopy. Cell Mol Biol (Noisy-le-grand) 42(1):103-110
109. Minqin R, Rajendran R, Pan N, Tan BK, Ong WY, Watt F, Halliwell B (2005) The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radical Biol Med 38(9):1206-1211. doi: 10.1016/j.freeradbiomed.2005.01.008
110. Sullivan JL (1981) Iron and the sex difference in heart disease risk. Lancet 1(8233):1293-1294
111. Stone NJ, Levy RI, Fredrickson DS, Verter J (1974) Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 49(3):476-488
112. Sullivan JL (2003) Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am Heart J 145(2):190-194. doi: 10.1067/mhj.2003.142
113. Kannel WB, Hjortland MC, McNamara PM, Gordon T (1976) Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85(4):447-452
114. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R (1992) High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 86(3):803-811
115. Danesh J, Appleby P (1999) Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 99(7):852-854
116. Finch CA, Cook JD, Labbe RF, Culala M (1977) Effect of blood donation on iron stores as evaluated by serum ferritin. Blood 50(3):441-447
117. Milman N, Kirchhoff M (1991) The influence of blood donation on iron stores assessed by serum ferritin and hemoglobin in a population survey of 1359 Danish women. Ann Hematol 63(1):27-32
118. Tuomainen TP, Salonen R, Nyyssonen K, Salonen JT (1997) Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ 314(7083):793-794
119. Meyers DG, Strickland D, Maloley PA, Seburg JK, Wilson JE, McManus BF (1997) Possible association of a reduction in cardiovascular events with blood donation. Heart 78(2):188-193
120. Ascherio A, Rimm EB, Giovannucci E, Willett WC, Stampfer MJ (2001) Blood donations and risk of coronary heart disease in men. Circulation 103(1):52-57
121. Meyers DG, Jensen KC, Menitove JE (2002) A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion 42(9):1135-1139
122. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW (2007) Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. J Am Med Assoc (JAMA) 297(6):603-610. doi: 10.1001/jama.297.6.603
123. Zacharski LR, Chow B, Lavori PW, Howes PS, Bell MR, DiTommaso MA, Carnegie NM, Bech F, Amidi M, Muluk S (2000) The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J 139(2 Pt 1):337-345
124. Zheng H, Huang X, Zhang Q, Katz SD (2006) Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int 69(4):679-684. doi: 10.1038/sj.ki.5000046
125. Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, Marx JJ (2002) Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32(Suppl 1):9-16
126. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl J Med 339(9):584-590. doi: 10.1056/NEJM199808273390903